Thank you.
I am pleased to provide a brief situation update. Over the past two weeks, there has been a considerable increase in the number of hospitalizations and deaths. While this trend is increasing, it's still lower than the peak period of the first wave—the first three weeks of June 2009.
Since October 29, 175 new hospitalizations and 6 new deaths have been reported. Since the outbreak began, we've seen a total of almost 1,800 hospitalized cases, of which 351 were in intensive care and 101 have died, unfortunately.
While there may be many things we know about this virus, the future remains a bit uncertain. We have a comprehensive approach. Ultimately, vaccine will be our best defence and by Christmas there should be enough for everyone who wants it. We also have national, provincial, and local plans. We have a stock of antivirals sufficient to treat all who need it, and we have enough backup supplies to provide any necessary support to provinces and territories.
This is thanks to a great deal of foresight from governments over many years. Canada's agreement for the domestic production of pandemic vaccine dates back to 2001. Canada entered into that contract to ensure capacity in Canada, so that we would be capable of meeting our needs for a large supply of vaccine produced domestically in a limited timeframe. The company had an established record in the production of seasonal flu vaccine. When this agreement was secured, it secured Canada's supply of H1N1 vaccine for all Canadians who need and want protection.
Other countries did not have such agreements in place, and some have had to buy multiple vaccine products from multiple suppliers, each with different indications. As it turns out, while we would all hope for more, Canada actually has the most secure and complete supply of vaccine in the world, with one of the world's highest percentages of people in the process of being immunized.
I'd like to clarify something that was said yesterday about the security of our domestic supply. GSK is devoting its entire domestic production capacity to producing and bottling vaccine to fill the Canadian order. The manufacturer cannot export finished pandemic vaccine in vials to any other customer, and it has not done so. The certainty and stability of supply from GSK has meant that, unlike other countries, Canada did not have to scramble to find a supplier. GSK has produced more antigen than it can bottle in Canada.
Rest assured that there will be enough vaccine for the whole population.
I'd like to express my sincere appreciation for the hard work and long hours that public health officials, health care workers, individuals, and governments at all levels are putting in across the country. This is no easy task. In under two weeks, we have immunized as many Canadians as we would normally do in two months. Rest assured, there will be enough vaccine for all.
Thank you.